Advances In™ Monogenic Kidney Disorders: Optimizing Diagnosis and Management in Pediatric & Adult Patients

Release Date: November 30, 2020
Expiration Date: November 30, 2021

Activity Overview

Monogenic kidney stone disorders include cystinuria, primary hyperoxaluria, and Dent disease. These diseases are characterized by urinary hyperexcretion of insoluble mineral salts, leading to recurrent kidney stones or increased renal calcium deposition. Patients with rare stone diseases are more likely to develop chronic kidney disease, which can progress to end-stage renal disease (ESRD). Failure to recognize these diseases may lead to diagnostic delays and preventable renal injury. In the past few years, studies have identified the clinical importance of determining if a patient’s cause of kidney stone disease is genetic. Studies suggest that 15% of patients who seek specialty care for their kidney stones and 30% of those younger than 25 years of age with recurring stones have a monogenic form of nephrolithiasis.

This program reviews the etiology, pathophysiology, presentation, and diagnosis of monogenic kidney stone disease and aims to increase clinicians’ knowledge of the current and emerging treatment options for patients with monogenic kidney stone disorders.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.

Target Audience

This online educational activity is directed toward adult and pediatric nephrologists, urologists, advanced practice clinicians, and medical specialists who treat monogenic kidney stone disorders, including PH1. Nurses and other healthcare professionals who would be involved in the diagnosis and management of PH1 will be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Review the etiology and pathophysiology of monogenic kidney stone disorders
• Examine the symptomatology, clinical presentation, and diagnosis of monogenic kidney stone disorders
• Analyze the latest data on the efficacy and safety of the management of kidney stone disorders and the evolving treatment options

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Kyle David Wood, MD
Assistant Professor
Department of Urology
University of Alabama at Birmingham
Birmingham, Alabama

Disclosures: Consultant: Alnylam Pharmaceuticals, Orfan Biotech, Novome Biotechnologies, Synlogic Therapeutics, Oxidien Therapeutics.

Lawrence A. Copelovitch, MD
Medical Director of Dialysis
Medical Director of Supply Chain
Clinical Associate Professor
Division of Nephrology
The Children’s Hospital of Philadelphia
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Disclosures: Lawrence A. Copelovitch, MD, has no relevant financial relationships with commercial interests.

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.